$-0.17 EPS Expected for Infinity Pharmaceuticals, Inc. (INFI); Century Casinos (CNTY) Sentiment Is 0.73

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Logo

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $-0.17 EPS on March, 21.They anticipate $0.03 EPS change or 21.43% from last quarter’s $-0.14 EPS. After having $0.23 EPS previously, Infinity Pharmaceuticals, Inc.’s analysts see -173.91% EPS growth. The stock increased 6.94% or $0.1 during the last trading session, reaching $1.54. About 219,967 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 16.67% since March 14, 2018 and is downtrending. It has underperformed by 21.04% the S&P500. Some Historical INFI News: 06/03/2018 – BRISTOL-MYERS SQUIBB CO – DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO; 27/03/2018 – BMY: FDA ACCEPTS OPDIVO APPLICATION FOR FOR PRIORITY REVIEW; 12/04/2018 – BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 – SEC FILING; 09/04/2018 – KEYTRUDA? (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor; 08/05/2018 – ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE? IL-12 AND KEYTRUDA? (PEMBROLIZUMAB) FOR TRIPLE NEGATIVE BREAST CANCER; 13/04/2018 – Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly; 25/04/2018 – European Commission Approves Bristol-Myers Squibb?s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma; 13/03/2018 – Merck Gets FDA Priority Review for Keytruda sBLA in Advanced Cervical Cancer; 08/03/2018 – Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 06/03/2018 – Bristol-Myers Squibb?s Opdivo? (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

Century Casinos Inc (CNTY) investors sentiment decreased to 0.73 in Q4 2018. It’s down -0.21, from 0.94 in 2018Q3. The ratio dropped, as 30 institutional investors increased or opened new equity positions, while 41 sold and decreased positions in Century Casinos Inc. The institutional investors in our database now hold: 21.64 million shares, down from 22.35 million shares in 2018Q3. Also, the number of institutional investors holding Century Casinos Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 29 Increased: 17 New Position: 13.

More notable recent Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news were published by: Nasdaq.com which released: “Health Care Sector Update for 03/06/2019: VLRX, OPTN, INFI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on March 06, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT – Nasdaq” published on March 06, 2019, Nasdaq.com published: “Health Care Sector Update for 03/06/2019: HZNP,INFI,HCR,VSTM,SRPT,LGND,NVS – Nasdaq” on March 06, 2019. More interesting news about Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) were released by: Prnewswire.com and their article: “Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA™ for $30 Million Gross Proceeds – PRNewswire” published on March 06, 2019 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie – Benzinga” with publication date: March 13, 2019.

Investors sentiment increased to 1.22 in Q4 2018. Its up 0.13, from 1.09 in 2018Q3. It improved, as 11 investors sold Infinity Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 14 raised stakes. 30.65 million shares or 3.89% more from 29.50 million shares in 2018Q3 were reported. The New York-based Blackrock has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Clear Harbor Asset Mngmt Limited Liability Corporation reported 0.02% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Qs Ltd Liability Company holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 157,150 shares. Raymond James Financial Svcs Advsrs holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 11,750 shares. Jane Street Grp Limited Liability Company reported 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Price T Rowe Assoc Inc Md reported 120,206 shares or 0% of all its holdings. Meeder Asset Management stated it has 1,761 shares. Fosun Intll invested 0.03% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Panagora Asset Mgmt stated it has 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Marshall Wace Llp has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Tower (Trc) holds 0% or 5,448 shares. Jacobs Levy Equity Mgmt holds 129,127 shares. Jpmorgan Chase And Communication has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Royal State Bank Of Canada stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Fmr Ltd Liability Corp has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Among 3 analysts covering Infinity Pharmaceuticals (NASDAQ:INFI), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Infinity Pharmaceuticals had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The stock has “Underweight” rating by JP Morgan on Monday, November 12. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Market Perform” rating given on Monday, November 12 by Wells Fargo.

Since October 1, 2018, it had 4 insider purchases, and 1 sale for $3.56 million activity. BVF PARTNERS L P/IL had bought 175,000 shares worth $209,913. 5,000 shares were sold by Perkins Adelene Q, worth $14,100 on Monday, October 1.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $87.58 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Century Casinos, Inc. operates as a casino entertainment firm worldwide. The company has market cap of $257.59 million. The firm develops and operates gaming establishments, as well as related lodging, restaurant, horse racing, and entertainment facilities. It currently has negative earnings. It owns and operates casinos in North America and Poland; a racetrack and entertainment center in Canada; and pari-mutuel off-track betting network in southern Alberta, Canada.

Awm Investment Company Inc. holds 1.83% of its portfolio in Century Casinos, Inc. for 1.14 million shares. Perritt Capital Management Inc owns 357,250 shares or 1.01% of their US portfolio. Moreover, Penn Capital Management Co Inc has 0.4% invested in the company for 546,096 shares. The Illinois-based Ariel Investments Llc has invested 0.36% in the stock. North Star Investment Management Corp., a Illinois-based fund reported 271,250 shares.

More notable recent Century Casinos, Inc. (NASDAQ:CNTY) news were published by: Nasdaq.com which released: “Century Casinos (CNTY) Q4 Earnings Lag Estimates, Revenues Top – Nasdaq” on March 12, 2019, also Seekingalpha.com with their article: “Century Casinos posts growth across all segments. – Century Casinos, Inc. (NASDAQ:CNTY) – Seeking Alpha” published on March 11, 2019, Nasdaq.com published: “Pre-Market Earnings Report for March 11, 2019 : ITRN, CNTY, SBPH – Nasdaq” on March 08, 2019. More interesting news about Century Casinos, Inc. (NASDAQ:CNTY) were released by: Benzinga.com and their article: “Earnings Scheduled For March 11, 2019 – Benzinga” published on March 11, 2019 as well as Nasdaq.com‘s news article titled: “Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications – Nasdaq” with publication date: February 14, 2019.

The stock increased 1.86% or $0.16 during the last trading session, reaching $8.75. About 89,854 shares traded or 2.54% up from the average. Century Casinos, Inc. (CNTY) has risen 4.19% since March 14, 2018 and is uptrending. It has underperformed by 0.18% the S&P500. Some Historical CNTY News: 09/05/2018 – Century Casinos 1Q Rev $40.6M; 25/04/2018 – Century Casinos Enters Vietnamese Gaming Market Via Agreements With Minh Chau Ltd; 25/04/2018 – Century Casinos enters Vietnamese gaming market; 30/03/2018 – Investor Expectations to Drive Momentum within Douglas Emmett, Century Casinos, BlackRock Capital Investment, Quotient Technolo; 09/05/2018 – CENTURY CASINOS INC QTRLY SHR $0.03; 29/05/2018 – Century Casinos Announces Opening of Century Casino in Bath, United Kingdom; 09/05/2018 – CENTURY CASINOS INC – BOOK VALUE PER SHARE AT MARCH 31, 2018 WAS $6.10; 09/03/2018 Century Casinos 4Q Loss/Shr 19c; 25/04/2018 – Century Casinos Acquires 51% of the Outstanding Common Stk of Hong Kong’s Golden Hospitality Limited; 22/04/2018 – DJ Century Casinos Inc, Inst Holders, 1Q 2018 (CNTY)

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart